Recent analyses of HCC treated with AtezoBev have highlighted that patients with an immune‐activated TME—characterised by greater infiltration of functional CD8+ T cells and reduced myeloid suppression—exhibit superior responses and prolonged survival compared to those with an immune‐exhausted phenotype [33]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.